Genetic information firm Invitae has partnered with genomic profiling company KEW to develop new comprehensive genomic profiling solutions so it can sequence tumour DNA on its next-generation sequencing (NGS) platform.

KEW’s new capabilities for somatic mutation detection will be integrated with Invitae’s diagnostic genetic testing panels, which were developed for hereditary cancers to enable better cancer care, from diagnosis until treatment.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Invitae’s germline testing analyses inherited genetic changes that enhance the risk of certain cancers, while KEW’s somatic testing evaluates acquired DNA alterations that can drive a tumour’s growth.

“KEW’s new capabilities for somatic mutation detection will be integrated with Invitae’s diagnostic genetic testing panels, which were developed for hereditary cancers to enable better cancer care.”

Invitae CEO Sean George said: “Broadening our ability to capture genetic information on both tumour biology and a patient’s inherited risk of disease while maintaining our commitment to lowering cost enhances Invitae’s ability to expand the market and enable affordable, high-quality precision care for more patients.”

KEW’s CancerPlex sequencing assay helps in detecting somatic mutations in 435 genes and allows assessment of tumour mutational burden and microsatellite instability to identify potential responders to immune checkpoint inhibitors.

Invitae will fund both the new development project and the integration of KEW’s technology into its platform and workflow.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

As part of the deal, the company will have access to KEW’s bioinformatics software and the CancerPlex sequencing assay.

KEW president and CEO Jerry Williamson said: “State-of-the-art bioinformatics has enabled Invitae to build out a uniquely scalable offering well suited to rapid integration with our proprietary algorithms for optimal and accurate genomic variant detection and curated knowledge base.

“We believe aligning these capabilities on a single platform will provide the basis for making molecular characterisation the standard of care.”

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact